Literature DB >> 2533444

Reduction in blood and urine glucose levels in streptozotocin and alloxan diabetes by phenazine methosulfate.

J O Akpan1.   

Abstract

The purpose of this investigation was to ascertain the ability of phenazine methosulfate (PMS) to improve the streptozotocin (STZ) and alloxan induced diabetic condition in vivo as determined by changes in blood and urine glucose levels and by alteration in the secretion of insulin by isolated islets. STZ and alloxan diabetes was induced in male albino rats (200-250 g body weight). A single injection of PMS (6.0 mg/kg) or nicotinamide (500 mg/kg) simultaneously with diabetic doses of either STZ or alloxan caused a significant reduction in blood and urine glucose levels three days after the injection. The reduction in glycemic levels was greater with PMS than with nicotinamide. Daily PMS (0.5 mg/kg) injection, initiated 5, 10, 20 or 30 days after the development of STZ- and alloxan-diabetes, caused a significant decrease in blood and urine glucose levels and also increased body weight determined 60 days after STZ or alloxan administration. These effects were observed even if the injections were initiated 20 or 30 days after the onset of the diabetic syndrome. Glucose stimulated insulin secretion was significantly inhibited by pre-incubation of isolated islets for one hour at 37 degrees C with either STZ or alloxan. However, insulin secretion was induced by PMS in the STZ or alloxan pretreated islets. Nicotinamide neither protected nor induced insulin secretion under similar conditions. The level of insulin secretion induced by PMS whether in the normal islets or in islets previously exposed to the B-cytotoxic agents were comparable in quantity to glucose (17 mM)-stimulated insulin secretion.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2533444     DOI: 10.1007/bf02581385

Source DB:  PubMed          Journal:  Acta Diabetol Lat        ISSN: 0001-5563


  13 in total

1.  THE ROLE OF DPNASE IN THE MECHANISM OF ACTION OF AN ANTITUMOR ALKYLATING AGENT ON EHRLICH ASCITES CELLS.

Authors:  E KUN; B LANGER; B ULRICH; H HOLZER; H GRUNICKE
Journal:  Proc Natl Acad Sci U S A       Date:  1964-12       Impact factor: 11.205

2.  Properties of preparations from the central nervous system which degrade coenzymes I and II; their connexion with carbohydrate metabolism.

Authors:  H McILWAIN
Journal:  Biochem J       Date:  1950-05       Impact factor: 3.857

3.  Pyridine nucleotide depletion in pancreatic islets associated with streptozotocin-induced diabetes.

Authors:  C K Ho; S A Hashim
Journal:  Diabetes       Date:  1972-07       Impact factor: 9.461

4.  Streptozotocin: depression of mouse liver pyridine nucleotides.

Authors:  P S Schein; S Loftus
Journal:  Cancer Res       Date:  1968-08       Impact factor: 12.701

5.  Method for the isolation of intact islets of Langerhans from the rat pancreas.

Authors:  P E Lacy; M Kostianovsky
Journal:  Diabetes       Date:  1967-01       Impact factor: 9.461

6.  Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancreatic islets.

Authors:  H Yamamoto; Y Uchigata; H Okamoto
Journal:  Nature       Date:  1981-11-19       Impact factor: 49.962

7.  Effect of diabetogenic nitrosourea on the activity of the pentose phosphate hunt in isolated islets.

Authors:  J O Akpan; P H Wright; W E Dulin
Journal:  Acta Diabetol Lat       Date:  1982 Jan-Mar

8.  6-Amnionicotinamide (6-AN) as a diabetogenic agent. In vitro and in vivo studies in the rat.

Authors:  H P Ammon; J Steinke
Journal:  Diabetes       Date:  1972-03       Impact factor: 9.461

9.  Insulin immunoassay by back-titration using alcohol precipitation of insulin-antibody complexes.

Authors:  D R Makulu; D Vichick; P H Wright; K E Sussman; P L Yu
Journal:  Diabetes       Date:  1969-10       Impact factor: 9.461

10.  Determinants of the selective toxicity of alloxan to the pancreatic B cell.

Authors:  W J Malaisse; F Malaisse-Lagae; A Sener; D G Pipeleers
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.